Background

• In 2019, the American Association for the Study of Liver Diseases (AASLD) - Infectious Diseases Society of America (ISDA) updated their guideline recommendations advocating for a multidisciplinary team of providers involved in the treatment of Hepatitis C virus (HCV) to increase access to care.
• This reframing of the HCV care continuum has compelled innovative practice models for clinical pharmacists. The current wait time for HCV treatment can take 6 12 weeks or longer from the time of provider referral to a gastroenterology appointment for HCV treatment consideration, resulting in delayed labs and therapy starts.
• Health system specialty pharmacies (HSSP) can bridge this gap by prescribing HCV treatment through collaborative practice agreements (CPAs).
  
  

Objectives

Evaluate the impact of a HSSP CPA by decreasing the time to the start of treatment for HCV access to care.

Read about the team's findings by downloading the Outcomes Study below.

Download the abstract: